ADRX

ADARx Pharmaceuticals Inc

19.35

Sep 25 • 3:59 PM ET +2.35 (13.82%)

18.99

Aftermarket • 7:52 PM ET -0.36 (-1.86%)

Healthcare Biotechnology USA Small NASD

Sep 25, 1:01 PMADARx pops 30% on Nasdaq debut after $446M upsized IPO at $17

Scroll to Statements

Index	-
Market Cap	1.46B
Enterprise Value	1.40B
Income	-
Sales	-
Book/sh	-2.46
Cash/sh	5.67
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	-
IPO	Sep 25, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	3.41
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	12.98
Current Ratio	12.98
Debt/Eq	0.06
LT Debt/Eq	0.05
Option/Short	No / No

EPS (ttm)	-
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-
Sales Q/Q	-
Earnings	-
EPS/Sales Surpr.	- -

Insider Own	-
Insider Trans	-
Inst Own	-
Inst Trans	-
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	0.00%
SMA50	0.00%
SMA200	0.00%
Trades

Shs Outstand	102.20M
Shs Float	-
Short Float	-
Short Ratio	-
Short Interest	-
52W High	- -
52W Low	- -
Volatility	- -
ATR (14)	4.21
RSI (14)	-
Beta	-
Rel Volume	-
Avg Volume	-
Volume	4,213,818

Perf Week	-
Perf Month	-
Perf Quarter	-
Perf Half Y	-
Perf YTD	-
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	-
Target Price	-
Prev Close	17.00
Price	19.35
Change %	13.82%

ADARx Pharmaceuticals, Inc. is a late-clinical-stage biotechnology company. It focuses on developing next-generation small interfering RNA (siRNA) therapeutics for diseases with significant unmet medical needs. The company was founded by Zhen Li in December 2019 and is headquartered in San Diego, CA.

Co-FounderDr. Zhen Li Ph.D.

Chief Scientific OfficerDr. Robert A. MacLeod Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ADRX

ADARx Pharmaceuticals Inc

Upgrade your Finviz experience